RECORDATI |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 49.1 EUR | +0.61% |
|
-1.52% | +0.55% |
| 04-24 | Global markets live: Heineken, AT&T Hasbro, Visa, Boeing... |  |
| 04-24 | CVC Said Mulling Options for Majority Stake in Recordati | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registration
Recordati S.p.A. specializes in the research, development, production and marketing of pharmaceutical products. Net sales break down by family of products as follows:
- pharmaceutical and OTC products (67.9%): for the treatment of viral infections, cardiovascular, dermatological, gynecological diseases, etc.;
- medicines for rare diseases (32.1%).
Net sales are distributed geographically as follows: Italy (15%), Europe (58.5%), America (17.5%), Australasia (6.2%) and Africa (2.8%).
Sector
Pharmaceuticals
Calendar
2024-05-08
- Q1 2024 Earnings Release
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
A-
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
10
Last Close Price
49.1
EUR
Average target price
52.14
EUR
Spread / Average Target
+6.19%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +0.55% | 10.79B | |
| +25.83% | 661B | |
| +27.00% | 566B | |
| -6.76% | 352B | |
| +20.34% | 332B | |
| +3.00% | 283B | |
| +13.09% | 231B | |
| +5.46% | 200B | |
| -9.61% | 195B | |
| -6.26% | 145B |
- Stock Market
- Equities
- REC Stock
- News Recordati
- Recordati Expects FY21 Results to Hit Lower End of Guidance Range
